1
|
Kobayashi W, Miyase T, Sano M, Umehara K,
Warashina T and Noguchi H: Prolyl endopeptidase inhibitors from the
roots of Lindera strychnifolia F. Vill. Biol Pharm Bull.
25:1049–1052. 2002. View Article : Google Scholar
|
2
|
Gan LS, Zheng YL, Mo JX, Liu X, Li XH and
Zhou CX: Sesquiterpene lactones from the root tubers of Lindera
aggregata. J Nat Prod. 72:1497–1501. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Ohno T, Takemura G, Murata I, Kagawa T,
Akao S, Minatoguchi S, Fujiwara T and Fujiwara H: Water extract of
the root of Lindera strychnifolia slows down the progression
of diabetic nephropathy in db/db mice. Life Sci. 77:1391–1403.
2005. View Article : Google Scholar
|
4
|
Wang F, Gao Y, Zhang L and Liu JK:
Bi-linderone, a highly modified methyl-linderone dimer from
Lindera aggregata with activity toward improvement of
insulin sensitivity in vitro. Org Lett. 12:2354–2357. 2010.
View Article : Google Scholar
|
5
|
Chang WA, Lin ES, Tsai MJ, Huang MS and
Kuo PL: Isolinderalactone inhibits proliferation of A549 human
non-small cell lung cancer cells by arresting the cell cycle at the
G0/G1 phase and inducing a Fas receptor and soluble Fas
ligand-mediated apoptotic pathway. Mol Med Rep. 9:1653–1659. 2014.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Yen MC, Shih YC, Hsu YL, Lin ES, Lin YS,
Tsai EM, Ho YW, Hou MF and Kuo PL: Isolinderalactone enhances the
inhibition of SOCS3 on STAT3 activity by decreasing miR-30c in
breast cancer. Oncol Rep. 35:1356–1364. 2016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Chuang CH, Wang LY, Wong YM and Lin ES:
Anti-metastatic effects of isolinderalactone via the inhibition of
MMP-2 and up regulation of NM23-H1 expression in human lung cancer
A549 cells. Oncol Lett. 15:4690–4696. 2018.
|
8
|
Rajina S, Kim WJ, Shim JH, Chun KS, Joo
SH, Shin HK, Lee SY and Choi JS: Isolinderalactone induces cell
death via mitochondrial superoxide- and STAT3-mediated pathways in
human ovarian cancer cells. Int J Mol Sci. 21:75302020. View Article : Google Scholar
|
9
|
Hwang JY, Park JH, Kim MJ, Kim WJ, Ha KT,
Choi BT, Lee SY and Shin HK: Isolinderalactone regulates the
BCL-2/caspase-3/PARP pathway and suppresses tumor growth in a human
glioblastoma multiforme xenograft mouse model. Cancer Lett.
443:25–33. 2019. View Article : Google Scholar
|
10
|
Park JH, Kim MJ, Kim WJ, Kwon KD, Ha KT,
Choi BT, Lee SY and Shin HK: Isolinderalactone suppresses human
glioblastoma growth and angiogenic activity in 3D microfluidic chip
and in vivo mouse models. Cancer Lett. 478:71–81. 2020. View Article : Google Scholar
|
11
|
Camelo-Piragua S and Kesari S: Further
understanding of the pathology of glioma: Implications for the
clinic. Expert Rev Neurother. 16:1055–1065. 2016. View Article : Google Scholar : PubMed/NCBI
|
12
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-Year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar
|
14
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Norden AD, Drappatz J and Wen PY:
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol.
5:610–620. 2009. View Article : Google Scholar
|
16
|
Ribatti D and Pezzella F: Vascular
co-option and other alternative modalities of growth of tumor
vasculature in glioblastoma. Front Oncol. 12:8745542022. View Article : Google Scholar
|
17
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar
|
18
|
Plate KH and Mennel HD: Vascular
morphology and angiogenesis in glial tumors. Exp Toxicol Pathol.
47:89–94. 1995. View Article : Google Scholar
|
19
|
Chi AS, Sorensen AG, Jain RK and Batchelor
TT: Angiogenesis as a therapeutic target in malignant gliomas.
Oncologist. 14:621–636. 2009. View Article : Google Scholar
|
20
|
Sisakht AK, Malekan M, Ghobadinezhad F,
Firouzabadi SNM, Jafari A, Mirazimi SMA, Abadi B, Shafabakhsh R and
Mirzaei H: Cellular conversations in glioblastoma progression,
diagnosis and treatment. Cell Mol Neurobiol. Apr 11–2022.(Epub
ahead of print). View Article : Google Scholar
|
21
|
Plate KH, Breier G, Weich HA and Risau W:
Vascular endothelial growth factor is a potential tumour
angiogenesis factor in human gliomas in vivo. Nature. 359:845–848.
1992. View
Article : Google Scholar : PubMed/NCBI
|
22
|
Gilbertson RJ and Rich JN: Making a
tumour's bed: Glioblastoma stem cells and the vascular niche. Nat
Rev Cancer. 7:733–736. 2007. View
Article : Google Scholar : PubMed/NCBI
|
23
|
Nomura M, Yamagishi S, Harada S, Hayashi
Y, Yamashima T, Yamashita J and Yamamoto H: Possible participation
of autocrine and paracrine vascular endothelial growth factors in
hypoxia-induced proliferation of endothelial cells and pericytes. J
Biol Chem. 270:28316–28324. 1995. View Article : Google Scholar : PubMed/NCBI
|
24
|
Yang J, Kim WJ, Jun HO, Lee EJ, Lee KW,
Jeong JY and Lee SW: Hypoxia-induced fibroblast growth factor 11
stimulates capillary-like endothelial tube formation. Oncol Rep.
34:2745–2751. 2015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Lee SW, Kim WJ, Choi YK, Song HS, Son MJ,
Gelman IH, Kim YJ and Kim KW: SSeCKS regulates angiogenesis and
tight junction formation in blood-brain barrier. Nat Med.
9:900–906. 2003. View
Article : Google Scholar : PubMed/NCBI
|
26
|
van Duinen V, Zhu D, Ramakers C, van
Zonneveld AJ, Vulto P and Hankemeier T: Perfused 3D angiogenic
sprouting in a high-throughput in vitro platform. Angiogenesis.
22:157–165. 2019. View Article : Google Scholar : PubMed/NCBI
|
27
|
Folkman J: Angiogenesis: An organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251. 2021.
View Article : Google Scholar
|
29
|
Holash J, Wiegand SJ and Yancopoulos GD:
New model of tumor angiogenesis: Dynamic balance between vessel
regression and growth mediated by angiopoietins and VEGF. Oncogene.
18:5356–5362. 1999. View Article : Google Scholar : PubMed/NCBI
|
30
|
Fine HA: Bevacizumab in glioblastoma-still
much to learn. N Engl J Med. 370:764–765. 2014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Schmidt NO, Westphal M, Hagel C, Ergün S,
Stavrou D, Rosen EM and Lamszus K: Levels of vascular endothelial
growth factor, hepatocyte growth factor/scatter factor and basic
fibroblast growth factor in human gliomas and their relation to
angiogenesis. Int J Cancer. 84:10–18. 1999. View Article : Google Scholar : PubMed/NCBI
|
32
|
Reiss Y, Machein MR and Plate KH: The role
of angiopoietins during angiogenesis in gliomas. Brain Pathol.
15:311–317. 2005. View Article : Google Scholar
|
33
|
Brat DJ, Bellail AC and Van Meir EG: The
role of interleukin-8 and its receptors in gliomagenesis and
tumoral angiogenesis. Neuro Oncol. 7:122–133. 2005. View Article : Google Scholar
|
34
|
Shih AH and Holland EC: Platelet-derived
growth factor (PDGF) and glial tumorigenesis. Cancer Lett.
232:139–147. 2006. View Article : Google Scholar
|
35
|
Di Tacchio M, Macas J, Weissenberger J,
Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M,
Herrlinger U, et al: Tumor vessel normalization, immunostimulatory
reprogramming, and improved survival in glioblastoma with combined
inhibition of PD-1, angiopoietin-2, and VEGF. Cancer Immunol Res.
7:1910–1927. 2019. View Article : Google Scholar : PubMed/NCBI
|
36
|
Lucero R, Zappulli V, Sammarco A, Murillo
OD, Cheah PS, Srinivasan S, Tai E, Ting DT, Wei Z, Roth ME, et al:
Glioma-derived miRNA-containing extracellular vesicles induce
angiogenesis by reprogramming brain endothelial cells. Cell Rep.
30:2065–2074.e4. 2020. View Article : Google Scholar : PubMed/NCBI
|
37
|
Li D, Zhang Z, Xia C, Niu C and Zhou W:
Non-coding RNAs in glioma microenvironment and angiogenesis. Front
Mol Neurosci. 14:7636102021. View Article : Google Scholar
|